New Therapeutic Approaches to Arterial Calcification Via Inhibition of Transglutaminase andβ-Catenin Signalin

Author(s): Mikhail Konoplyannikov, Maria Nurminskaya

Journal Name: Current Pharmaceutical Design

Volume 20 , Issue 37 , 2014

Become EABM
Become Reviewer

Abstract:

Arterial calcification (AC) is a hallmark of many serious diseases, including atherosclerosis, chronic kidney disease, and diabetes. AC may also develop as a side-effect of therapy with anticoagulants, such as warfarin which is widely used for prophylaxis of thrombosis. In our studies, we established the relation between warfarin-induced AC and activation of enzyme transglutaminase 2 (TG2) and β-catenin signaling. We showed that TG2-specific inhibitor KCC-009 significantly attenuated the damaging effects of warfarin on arterial tissue. A similar protective effect was also achieved with a dietary bioflavonoid quercetin that inhibits TG2 and β-catenin signaling. We have shown that quercetin intercepts the chondrogenic transformation of vascular smooth muscle and also drastically attenuates calcifying cartilaginous metaplasia in another model of AC caused by genetic loss of matrix gla protein (MGP). These findings suggest that quercetin may be considered as a promising anti-AC therapeutic in the clinical settings of warfarin supplementation and MGP dysfunction. Further studies are required to test the efficacy of quercetin on other types of AC.

Keywords: Arterial calcification, transglutaminase 2, β-catenin, warfarin, quercetin.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 20
ISSUE: 37
Year: 2014
Page: [5811 - 5820]
Pages: 10
DOI: 10.2174/1381612820666140212205059
Price: $65

Article Metrics

PDF: 42